Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus After Bare Metal Stent Implantation: A Nationwide Cohort Study

Overview

Journal Acta Cardiol Sin

Date 2019 Aug 3

PMID 31371901

Citations 6

Authors

Chun-Wei Lee

Fu-Fei Tsai

Min-I Su

Hung-I Yeh

Yi-Ting Chiang

Chi-Feng Hsieh

Chun-Yen Chen

Affiliations

Soon will be listed here.

Abstract

Background: To investigate whether there is an increased risk of cardiovascular (CV) events in patients with diabetes associated with adding proton pump inhibitors (PPIs) to clopidogrel (CLO) therapy after bare-metal stent (BMS) deployment.

Methods: We used the National Health Insurance Research Database to conduct this retrospective cohort study. We enrolled 6,757 patients with diabetes who underwent BMS deployment and received CLO with/without PPIs for 90 days (6,243 in the CLO subgroup and 514 in the CLO plus PPI subgroup). The endpoints were acute coronary syndrome and re-admission for revascularization (PCI or coronary artery bypass graft surgery) after 3, 6, and 12 months.

Results: The patients who received CLO with PPIs had no significant increase in adverse CV events compared to those without PPIs within 1 year after BMS deployment [3-month hazard ratio (HR) = 0.87, 95% confidence interval (CI), 0.65-1.15; 6 months, HR = 0.95, 95% CI, 0.78-1.15; 1 year, HR = 0.60, 95% CI, 0.81-1.12].

Conclusions: In patients with diabetes undergoing BMS deployment, there was no evidence of an increased risk of CV events among concomitant users of CLO and PPIs. Our results indicate that the use of PPIs may not modify the protective effect of CLO after BMS implantation.

Citing Articles

Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view.

Abrignani M, Lombardo A, Braschi A, Renda N, Abrignani V World J Cardiol. 2023; 15(8):375-394.

PMID: 37771340 PMC: 10523195. DOI: 10.4330/wjc.v15.i8.375.

CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.

Ramste M, Ritvos M, Hayrynen S, Kiiski J, Niemi M, Sinisalo J Clin Transl Sci. 2023; 16(10):2010-2020.

PMID: 37551775 PMC: 10582682. DOI: 10.1111/cts.13608.

Considering ISCHEMIA in the Context of FAME and FAME 2: A Call for the Universal Adoption of Invasive Ischemia-Guided Coronary Intervention Approach in Chronic Coronary Syndrome.

Wang T Acta Cardiol Sin. 2020; 36(2):93-96.

PMID: 32201458 PMC: 7062808. DOI: 10.6515/ACS.202003_36(2).20200303A.

Clinical Impact of High-Sensitivity Cardiac Troponin T on the Chronic Phase of Stable Angina after a Successful Initial Percutaneous Coronary Intervention.

Okamoto H, Kume T, Koyama T, Tamada T, Yamada R, Neishi Y Acta Cardiol Sin. 2020; 36(1):16-23.

PMID: 31903004 PMC: 6933491. DOI: 10.6515/ACS.202001_36(1).20190704C.

Appropriate Use of Dual Antiplatelet Therapy.

Wang K, Wang T Acta Cardiol Sin. 2019; 35(4):412-414.

PMID: 31371902 PMC: 6656976. DOI: 10.6515/ACS.201907_35(4).20190715A.

References

Aihara H, Sato A, Takeyasu N, Nishina H, Hoshi T, Akiyama D . Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry. Catheter Cardiovasc Interv. 2012; 80(4):556-63. DOI: 10.1002/ccd.23327. View

Gupta E, Bansal D, Sotos J, Olden K . Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2009; 55(7):1964-8. DOI: 10.1007/s10620-009-0960-8. View

Abbott J, Voss M, Nakamura M, Cohen H, Selzer F, Kip K . Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol. 2007; 50(21):2029-36. DOI: 10.1016/j.jacc.2007.07.071. View

Agewall S, Cattaneo M, Collet J, Andreotti F, Lip G, Verheugt F . Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013; 34(23):1708-13, 1713a-1713b. DOI: 10.1093/eurheartj/eht042. View

Little R, Rubin D . Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health. 2000; 21:121-45. DOI: 10.1146/annurev.publhealth.21.1.121. View

Serruys P, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G . A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331(8):489-95. DOI: 10.1056/NEJM199408253310801. View

Cutlip D, Chauhan M, Baim D, Ho K, Popma J, Carrozza J . Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002; 40(12):2082-9. DOI: 10.1016/s0735-1097(02)02597-4. View

Banerjee S, Weideman R, Weideman M, Little B, Kelly K, Gunter J . Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011; 107(6):871-8. DOI: 10.1016/j.amjcard.2010.10.073. View

Li Y, Fang C, Hsieh I, Huang W, Lin T, Sung S . 2018 Expert Consensus on the Management of Adverse Effects of Antiplatelet Therapy for Acute Coronary Syndrome in Taiwan. Acta Cardiol Sin. 2018; 34(3):201-210. PMC: 5968336. DOI: 10.6515/ACS.201805_34(3).20180302A. View

10.

Yeh H, Hsieh C, Tsai Y, Huang W . Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan. Clin Ther. 2012; 34(4):885-93. DOI: 10.1016/j.clinthera.2012.02.024. View

11.

Schmidt M, Johansen M, Robertson D, Maeng M, Kaltoft A, Jensen L . Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther. 2011; 35(1):165-74. DOI: 10.1111/j.1365-2036.2011.04890.x. View

12.

Bhurke S, Martin B, Li C, Franks A, Bursac Z, Said Q . Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012; 32(9):809-18. PMC: 3531962. DOI: 10.1002/j.1875-9114.2012.01112.x. View

13.

van Boxel O, van Oijen M, Hagenaars M, Smout A, Siersema P . Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol. 2010; 105(11):2430-6. DOI: 10.1038/ajg.2010.334. View

14.

Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat M . Biological responses in stented arteries. Cardiovasc Res. 2013; 99(2):353-63. DOI: 10.1093/cvr/cvt115. View

15.

Li X, Andersson T, Ahlstrom M, Weidolf L . Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32(8):821-7. DOI: 10.1124/dmd.32.8.821. View

16.

Levine G, Bates E, Blankenship J, Bailey S, Bittl J, Cercek B . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and.... J Am Coll Cardiol. 2011; 58(24):e44-122. DOI: 10.1016/j.jacc.2011.08.007. View

17.

Lee C, Tsai F, Su M, Yeh H, Chiang Y, Hsieh C . Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Bare Metal Stent Implantation: A Nationwide Cohort Study. Acta Cardiol Sin. 2019; 35(4):402-411. PMC: 6656978. DOI: 10.6515/ACS.201907_35(4).20190108B. View

18.

Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28(1):88-136. DOI: 10.1093/eurheartj/ehl260. View

19.

Bhatt D, Cryer B, Contant C, Cohen M, Lanas A, Schnitzer T . Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363(20):1909-17. DOI: 10.1056/NEJMoa1007964. View

20.

Cardoso R, Benjo A, DiNicolantonio J, Garcia D, Macedo F, El-Hayek G . Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015; 2(1):e000248. PMC: 4488889. DOI: 10.1136/openhrt-2015-000248. View